292PBRCA1/2 testing in HER2- advanced breast cancer (ABC): Results from the European component of a multi-country real-world study

ConclusionsIn this analysis of adult women with ABC, both HR+/HER2- and TNBC pts with a known FHx of BC or OC (vs no known FHx) were more likely to receive BRCA1/2 testing but testing rates are still low especially among HR+/HER2- pts. With the broadening of BRCA1/2 testing eligibility criteria in BC guidelines, opportunities exist to increase BRCA1/2 testing in EU5.Legal entity responsible for the studyPfizer Inc.FundingPfizer Inc.DisclosureM.P. Lux: Honoraria (self), Advisory / Consultancy: Pfizer Inc.; Honoraria (self), Advisory / Consultancy: Novartis; Honoraria (self), Advisory / Consultancy: Lilly; Honoraria (self), Advisory / Consultancy: AstraZeneca; Honoraria (self), Advisory / Consultancy: Roche; Honoraria (self), Advisory / Consultancy: Genomic Health; Honoraria (self), Advisory / Consultancy: medac; Honoraria (self), Advisory / Consultancy: Gr ünethal; Honoraria (self), Advisory / Consultancy: Tesaro; Honoraria (self), Advisory / Consultancy: Eisai. A. Niyazov: Shareholder / Stockholder / Stock options, Full / Part-time employment: Pfizer Inc. All other authors have declared no conflicts of interest. Table: 292PHR+/HER2- with FHx (n =  321)HR+/HER2- without FHx (n = 2,953)TNBC with FHx (n = 178)TNBC without FHx (n = 789)Pts tested, N (%)116 (36)476 (16)99 (56)234 (30)P value<.001<.001
Source: Annals of Oncology - Category: Cancer & Oncology Source Type: research